共 135 条
[1]
Bonello L(2010)Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 919-33
[2]
Tantry US(2009)P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use Eur Heart J 30 1964-77
[3]
Marcucci R(2009)Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 354-62
[4]
Blindt R(2010)Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet 376 1312-9
[5]
Angiolillo DJ(2010)Effects of CYP2C19 genotype on outcomes of clopidogrel treatment N Engl J Med 363 1704-14
[6]
Becker R(2010)Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 1821-30
[7]
Bhatt DL(2011)Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy Thromb Haemost 105 933-44
[8]
Cattaneo M(2010)Prognostic value of chronic kidney disease in patients with coronary heart disease: role of estimating equations Atherosclerosis 211 342-7
[9]
Collet JP(2004)A validated prediction model for all forms of acute coronray syndrome. Estimating the risk of 6-months post-discharge death in an international registry JAMA 291 2727-33
[10]
Cuisset T(2010)Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 1320-8